CWLXFOTCMedicinal Chemicals & Botanical ProductsFiscal year ends March 31
C21 Investments Inc.
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 20-F on Jun 12, 2026
Share price
Not available yet
Price, market cap and P/E appear here once daily prices are connected.
C21 Investments statistics
Financials through Mar 31, 2026, price-based ratios appear once a share price is available, median of Medicinal Chemicals & Botanical Products companies for comparison
Income (trailing twelve months)
| Measure | C21 Investments | Industry median |
|---|---|---|
| Revenue | $32.61M | $57.94M |
| Gross Profit | $13.61M | $90.47M |
| Operating Income | $2.28M | -$21.44M |
| Pretax Income | $1.38M | -$14.45M |
| Net Income | -$3.24M | -$22.46M |
| EBITDA | $4.06M | -$16.91M |
| EPS (Diluted) | -$0.03 | -$0.83 |
Margins
| Measure | C21 Investments | Industry median |
|---|---|---|
| Gross Margin | 41.7% | 52.3% |
| Operating Margin | 6.99% | -44.5% |
| Pretax Margin | 4.23% | -13.0% |
| Profit Margin | -9.95% | -39.2% |
| EBITDA Margin | 12.4% | -31.3% |
| FCF Margin | 3.43% | -8.85% |
Returns
| Measure | C21 Investments | Industry median |
|---|---|---|
| Return on Equity (ROE) | -12.8% | -53.1% |
| Return on Assets (ROA) | -5.96% | -41.0% |
| Return on Invested Capital (ROIC) | 4.91% | -32.0% |
| Return on Capital Employed (ROCE) | 4.74% | -37.8% |
Growth
| Measure | C21 Investments | Industry median |
|---|---|---|
| Revenue Growth (3Y CAGR) | -0.37% | 2.25% |
| Revenue Growth (5Y CAGR) | -2.86% | 6.42% |
Balance sheet
| Measure | C21 Investments | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $2.23M | $62.42M |
| Net Cash (Debt) | $2.23M | $15.68M |
| Net Cash Per Share | $0.02 | $0.66 |
| Equity (Book Value) | $25.43M | $48.79M |
| Book Value Per Share | $0.22 | $1.36 |
| Tangible Book Value | -$9.51M | $23.06M |
| Working Capital | $1.92M | $75.77M |
Financial position
| Measure | C21 Investments | Industry median |
|---|---|---|
| Current Ratio | 1.30 | 3.30 |
| Quick Ratio | 0.36 | 2.39 |
| Interest Coverage | 12.17 | -7.12 |
Cash flow (trailing twelve months)
| Measure | C21 Investments | Industry median |
|---|---|---|
| Operating Cash Flow | $1.36M | -$12.35M |
| Capital Expenditures | -$244.84K | -$1.06M |
| Free Cash Flow | $1.12M | -$20.28M |
| FCF Per Share | $0.01 | -$0.42 |
Efficiency
| Measure | C21 Investments | Industry median |
|---|---|---|
| Asset Turnover | 0.60 | 0.38 |
| Inventory Turnover | 4.14 | 2.67 |
Shares
| Measure | C21 Investments | Industry median |
|---|---|---|
| Shares Outstanding | 117,836,000 | 58,179,650 |
| Float | 117,836,000 | 49,173,100 |
| Shares Held by Insiders | 0.00% | 11.6% |
Taxes
| Measure | C21 Investments | Industry median |
|---|---|---|
| Income Tax | $4.61M | $91.50K |
| Effective Tax Rate | 334.7% | 20.6% |
Scores
| Measure | C21 Investments | Industry median |
|---|---|---|
| Piotroski F-Score | 7 | 4 |
| Beneish M-Score | -3.31 | -2.62 |
Calculated by StockData from C21 Investments's SEC filings. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.